Product Information
NYSTATIN-TRIAMCINOLONE CREAM is a generic product labeled by Lupin Pharmaceuticals Inc., priced at $0.2246 per GM under NDC 68180054502. Its NADAC has been published 395 times since Mar 13, 2019.
FDA first approved this application on May 31, 2018. Its Orange Book therapeutic-equivalence code is AT.
The Low Outlier badge above means this manufacturer's average price in the Nystatin and Triamcinolone Acetonide market falls below Q1 − 1.5·IQR across all competing manufacturers. We only apply this flag in markets with four or more competitors. Full definition: glossary → outlier.
Strength
100000; 1 [USP'U]/g; mg/g
Manufacturer
Lupin Pharmaceuticals Inc.NDC
68180054502
Classification
Generic
Dosage Form
CREAM
Route
TOPICAL
Effective Date
9/23/2026
Active Ingredients
NYSTATIN; TRIAMCINOLONE ACETONIDEApproval Type
Generic (ANDA)
FDA Application
ANDA208205FDA Approved
5/31/2018
TE Code
AT
On Market Since
11/29/2018
Pharmacological Classes
Price Statistics
The NADAC for NYSTATIN-TRIAMCINOLONE CREAM has been published 395 times since Mar 13, 2019, and over the history we have for it it has declined 77.6%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.2246 per GM |
|---|---|
| All-time high | $1.0028 (Mar 13, 2019) |
| All-time low | $0.2047 (Nov 20, 2024) |
| 52-week high | $0.2667 |
| 52-week low | $0.2127 |
| Median price | $0.4132 |
| Average price | $0.4327 |
| Largest weekly change | +81.7% (Aug 21, 2024) |
| Weeks tracked | 395 |
| Tracking since | Mar 13, 2019 |
Generic Alternatives
The matcher finds 4 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 15% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Lupin Pharmaceuticals Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Nystatin and Triamcinolone Acetonide market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Corticosteroid class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of NYSTATIN-TRIAMCINOLONE CREAM?
The current National Average Drug Acquisition Cost (NADAC) for NYSTATIN-TRIAMCINOLONE CREAM, manufactured by Lupin Pharmaceuticals Inc., is $0.2246 per GM (NDC 68180054502), effective Sep 30, 2026.
How has the price of NYSTATIN-TRIAMCINOLONE CREAM changed over time?
Over the history we have for it, the NADAC for NYSTATIN-TRIAMCINOLONE CREAM has declined 77.6%. It has been tracked across 395 weekly CMS publications since Mar 13, 2019.
What are the highest and lowest recorded NADAC prices for NYSTATIN-TRIAMCINOLONE CREAM?
Since Mar 13, 2019, the NADAC for NYSTATIN-TRIAMCINOLONE CREAM has ranged from a low of $0.2047 (Nov 20, 2024) to a high of $1.0028 (Mar 13, 2019), with a median of $0.4132 per GM.
Are there cheaper alternatives to NYSTATIN-TRIAMCINOLONE CREAM?
Yes. 4 manufacturers publish a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, NYSTATIN-TRIAMCINOLONE CREAM, is $0.1916 per GM — about 15% below NYSTATIN-TRIAMCINOLONE CREAM.
Who manufactures NYSTATIN-TRIAMCINOLONE CREAM?
NYSTATIN-TRIAMCINOLONE CREAM (NDC 68180054502) is labeled by Lupin Pharmaceuticals Inc., and CMS classifies it as a generic product.